Max Planck, Alnylam Attorneys Argue UMass Letter Shows Max Planck Owns Tuschl-II Inventions | GenomeWeb

By Doug Macron

A letter sent in 2004 by officials at the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology to the University of Massachusetts indicates that RNAi intellectual property at the heart of an ongoing legal battle belongs to the Max Planck Institute and therefore should be viewed as a confirmation of the ownership of the disputed IP, attorneys for plaintiffs Max Planck and Alnylam Pharmaceuticals argued this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.